An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
United Therapeutics Corporation (NASDAQ: UTHR) announced it will release its second quarter 2022 financial results on August 3, 2022, prior to market opening. A public webcast will follow at 9:00 a.m. ET on the same day, accessible via their website. United Therapeutics operates as a public benefit corporation, focusing on innovative therapies for patients and organ transplant technologies while aiming for superior financial performance and environmentally sustainable practices. Forward-looking statements are included in the release, cautioning potential risks and uncertainties.
Positive
None.
Negative
None.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.
United Therapeutics will host a public webcast Wednesday, August 3, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one week and can be accessed at the same location.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good.
We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-sensitive energy utilization.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose, providing superior financial performance for shareholders, and providing our communities with earth-sensitive energy utilization. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 27, 2022 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
When will United Therapeutics report its second quarter 2022 financial results?
United Therapeutics will report its second quarter 2022 financial results on August 3, 2022, before the market opens.
What time is the United Therapeutics public webcast?
The public webcast by United Therapeutics will take place at 9:00 a.m. Eastern Time on August 3, 2022.
How can I access the United Therapeutics webcast?
The webcast can be accessed via the United Therapeutics website at https://ir.unither.com/events-and-presentations.
What is the focus of United Therapeutics as a public benefit corporation?
As a public benefit corporation, United Therapeutics aims to develop novel pharmaceutical therapies and technologies that enhance organ transplant availability, alongside ensuring superior financial performance.